Perspective On Continuous Processing: Trends, Drivers And Strategies

By Nitin Naik, Global Practice Leader, Global Vice President, Transformational Health, Frost & Sullivan

The era of biopharmaceuticals and targeted therapies ushered in the age of precision healthcare. Better understanding of disease heterogeneity and identification of disease targets has fostered collaboration between pharmaceutical companies, bio-filtration systems manufacturers and CDMOs to launch new drugs for treatment of oncology, cardiology and metabolic diseases.  

This phenomenal infrastructure has established a solid launch pad for continuous processing technologies to gain critical mass and enable a highly responsive ecosystem that can pivot around real-time monitoring and quality control, optimized decision making, reduced costs, and improved patient outcomes.

Frost & Sullivan recently invited industry leaders in biopharmaceutical manufacturing to participate in a new and unique thought leadership forum, our Virtual Think Tank series. This forum brought together leading minds in manufacturing to discuss challenges, strategies, techniques, and barriers to new technology implementation in downstream processing.

Learn what strategies they recommend adopting to be successful in the transformational journey to adopt fully continuous processing.